# MOTS-c: A Promising Peptide for Protecting Against Acetaminophen-Induced Liver Injury

Canonical source: https://retacompare.com/research/mots-c-a-promising-peptide-for-protecting-against-acetaminophen-induced-liver-injury

Mitochondrial & Longevity · 2026-02-27


    MOTS-c shows potential in protecting against acetaminophen-induced liver injury by targeting the MAPK signaling pathway. This mitochondrial-derived peptide has previously demonstrated hepatoprotective effects in conditions such as nonalcoholic steatohepatitis and hepatitis B virus infection. The current study explores its therapeutic potential specifically in acetaminophen-induced liver injury, a significant cause of acute liver failure globally.

 What this study examined

The study investigated the effects of MOTS-c on acetaminophen-induced liver injury (AILI) using a male C57BL/6 mouse model. Researchers administered acetaminophen at a dose of 300 mg/kg via intraperitoneal injection to induce liver injury. Following this, they evaluated the therapeutic effects of MOTS-c through various methods, including behavioral tests, qPCR, western blotting, ELISA, immunohistochemistry, immunofluorescence, and TUNEL staining.

 Why it matters for MOTS-c research

The findings of this study are significant for the ongoing research into MOTS-c as a therapeutic agent. Given the lack of effective treatments for AILI, understanding how MOTS-c can mitigate liver damage presents a valuable avenue for future research. The study not only highlights MOTS-c's protective properties but also elucidates the underlying mechanisms through which it operates, particularly its interaction with the MAPK signaling pathway.

 Key findings

MOTS-c levels were significantly reduced in the plasma and liver tissues of AILI mice compared to controls.

Administration of MOTS-c reduced elevated AST and ALT levels, indicating decreased liver injury.

The peptide treatment alleviated histopathological liver damage and other markers of liver injury.

MOTS-c suppressed the release of pro-inflammatory factors and macrophage infiltration induced by acetaminophen.

TUNEL staining confirmed that MOTS-c treatment significantly reduced apoptosis in liver cells.

MOTS-c inhibited the phosphorylation of MAPK pathway components, including ERK, JNK, and p38.

 How MOTS-c works (background)

MOTS-c is a mitochondrial-derived peptide known for its role in regulating metabolic processes and cellular stress responses. This peptide has been shown to exert protective effects against oxidative stress and inflammation, key contributors to liver injury. In the context of AILI, MOTS-c's mechanism involves the inhibition of the MAPK signaling pathway, which is activated during liver injury and leads to increased oxidative stress and inflammation. By suppressing the phosphorylation of MAPK components, MOTS-c effectively reduces the damaging effects associated with acetaminophen toxicity.

 Practical takeaways for researchers

Researchers exploring the therapeutic potential of MOTS-c should consider its role in modulating oxidative stress and inflammation in liver injury models. The findings from this study suggest that MOTS-c could serve as a candidate for further investigation in the treatment of AILI and possibly other liver-related disorders. Additionally, understanding the specific pathways through which MOTS-c operates may provide insights for developing targeted therapies that leverage its protective effects.

 FAQ

 What is MOTS-c?

MOTS-c is a mitochondrial-derived peptide that has been shown to have protective effects in various liver conditions, including acetaminophen-induced liver injury.

 How does MOTS-c protect the liver?

MOTS-c protects the liver primarily by suppressing oxidative stress and inflammation through the inhibition of the MAPK signaling pathway.

 What are the implications of this research?

This research suggests that MOTS-c could be a promising therapeutic candidate for treating acetaminophen-induced liver injury, highlighting the need for further studies in this area.

 Source: PubMed · Protein Pept Lett · published 2026-02-27.

## Sources

- PubMed · Protein Pept Lett: https://pubmed.ncbi.nlm.nih.gov/41764620/